Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects.
Normal subjects and patients with adult-onset diabetes received 10 gm. of aspirin in four days. On the fourth day, the fasting serum glucose and the glucose response to oral glucose were decreased in both groups. These changes were associated with increased levels of serum insulin and pancreatic glucagon, although the glucagon responses to oral glucose were unchanged. In the diabetic patients, aspirin therapy was followed by a decreased glucose response to I.V. glucose and by the appearance of an early insulin peak, which could not be demonstrated before treatment. Aspirin did not affect the I.V. glucose tolerance in normal subjects, although it did enhance the early insulin peak. A decrease in the fasting levels of free fatty acids was noted in both groups, whereas the fasting level of triglycerides decreased only in the diabetic patients. Cholesterolemia did not change in either group. A few preliminary observations indicate that, in normal subjects, ibuprofen and ketoprofen, two other presumed prostaglandin inhibitors, did not affect fasting glycemia, glucose tolerance, or the insulin response to glucose. No changes were noted after the administration of placebo.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001786:Blood Glucose / Q000032:analysis*; D003920:Diabetes Mellitus / Q000097:blood*; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D007660:Ketoprofen / Q000494:pharmacology; D008875:Middle Aged; D010919:Placebos
D001786:Blood Glucose; D007328:Insulin; D010919:Placebos; D005934:Glucagon; D007660:Ketoprofen; D005947:Glucose; D001241:Aspirin; D007052:Ibuprofen